Loading animation
  • Home
  • About us View About us's child pages
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages
      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages
      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages
      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages
      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2021
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us

Please use the arrows to navigate to the sub pages

  • About us View About us's child pages

    About us

    Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys®  technology.

    Explore this section
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages

    What we do

    Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.

    Explore this section
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages

      MED3000

      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages

      TPR100

      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages

      Other products

      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages

      Products FAQ's

      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages

    Investor centre

    Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.

    WEBCASTS

    Explore this section
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages

      Videos and webcasts

      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages

      Shareholder centre

      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2021
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages

    Media

    This section contains the latest RNS, news and videos.

    Explore this section
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
  • About us View About us's child pages
    • Who we are
    • Our business model
    • Our strategy
    • Board of Directors
  • What we do View What we do's child pages
    • Our technology
    • Our product development pipeline
    • MED3000 View MED3000's child pages
      • MED3000 Overview
      • MED3000 Clinical Programme
      • MED3000 Commercial potential
    • TPR100 View TPR100's child pages
      • TPR100 Clinical Data
      • TPR100 Commercial potential
    • Other products View Other products's child pages
      • TIB200
      • CBD100
      • CSD500
    • Products FAQ's View Products FAQ's's child pages
      • DermaSys® FAQs
      • MED3000 FAQs
      • MED2005 FAQs
      • TPR100 FAQs
      • CBD100 FAQs
  • Investor centre View Investor centre's child pages
    • Share price chart
    • Corporate documentation
    • Videos and webcasts View Videos and webcasts's child pages
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre View Shareholder centre's child pages
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research View Analyst Research's child pages
        • 2021
        • 2020
        • 2019
    • Corporate Governance
    • AIM rule 26
  • Media View Media's child pages
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us

    Products FAQ's

    • Home
    • What we do
    • Products FAQ's

    DermaSys<sup>®</sup> FAQs

    • DermaSys® FAQs
    • MED3000 FAQs
    • MED2005 FAQs
    • TPR100 FAQs
    • CBD100 FAQs
    • What is DermaSys®?

      Futura’s unique transdermal technology DermaSys® enables targeted and rapid delivery of clinically proven effective medical treatments through the skin. 

      Our transdermal technology DermaSys® is tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action offering improvements over existing products creating novel indications with compelling commercial potential. This means that our products are highly differentiated in their markets while avoiding the risks normally associated with the development of new molecules.

      DermaSys® is a versatile normally clear, odourless gel uniquely formulated using  solvent components  and/or  diffusion enhancers tailored for each product, to suit the specific therapeutic indication and desired speed of onset and duration of action. Each product is formulated to maximise its benefits for patients and consumers.

    • What is the full IP position of DermaSys® Technology and all its formulations?

      DermaSys® is a proprietary transdermal technology platform with very strong IP offering a high level of product differentiation compared to existing marketed treatments. Each new unique formulation offers the opportunity for additional patent applications and potential patent protection.

    • What is MED3000?

      MED3000, our lead product, is a topical gel which utilises our proprietary technology DermaSys®, developed specifically for the treatment of erectile dysfunction (“ED”). MED3000 is a fast-acting topical treatment which has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market.

    • What is the difference between MED2005 and MED3000?

      MED3000 is the codename for a formulation of DermaSys® developed specifically for the treatment of ED. MED3000 is a unique formulation of DermaSys® using volatile and non-volatile components tailored for the treatment of ED.

    • How does MED3000 work?

      MED3000 is a topical gel applied directly to the head (glans) of the penis for the treatment of ED.

      MED3000 works through an evaporative and unique mode of action.  MED3000’s combination of volatile solvent components creates an evaporative and novel action that stimulates nerve sensors in the highly innervated glans penis rapidly, leading to smooth muscle relaxation, tumescence and erection.

       

    • What is the regulatory pathway for a medical device? Why has Futura decided to go down this route?

      A medical device is described within the EU as a product which does not achieve its principal intended action on the human body by pharmacological, immunological or metabolic means.

      Registration of MED3000 as a medical device is endorsed by both EU and US regulatory authorities. and is potentially a fast track and lower cost route to market  The Company anticipates certification and CE marking in Europe by end May 2021 as a Class II(b) medical device, and filing for approval in USA as a De Novo medical device in 2022. As the drug-free formulation is regarded as low risk,  free sale (OTC) designation is anticipated.

    • Can I request a sample of MED3000?

      Futura has retained specialist corporate advisers to assist the company in the appointment of world-wide distribution partners.  Once appointed all marketing and marketing aspects of MED3000 (including any samples they may choose to provide) will be handled by them.

    • How can I buy MED3000? Is MED3000 available for purchase?

      MED3000 is currently not available for purchase.

      European approval for MED3000 will be final upon issuance of a Medical Device Regulation certificate by the EU Notified Body which is expected before the end of May 2021.  Futura is also in discussions to out-license the marketing and distribution rights of MED3000 for the UK as well as other countries and once agreed all distribution will be handled by them.

    • When will MED3000 be on the market in the EU?

      In March 2020, Futura announced that the EU Notified Body had successfully completed its review of the Company's Technical Dossier for MED3000 with a recommendation to certify MED3000 as a Class 2B approved medical device. European approval for MED3000 will be final upon issuance of a Medical Device Regulation certificate by the Notified Body which is expected before the end of May.

      [A Notified Body is an organisation designated by EU regulators to assess the conformity of medical devices before being placed on the market.]

      Once the certificate is received, Futura's breakthrough, topical gel formulation MED3000 will become the first pan-European topical treatment for erectile dysfunction ("ED") available without the need of a doctor's prescription.

      Futura has retained specialist corporate advisers to assist the company in the appointment of world-wide distribution partners.  Once appointed all marketing and marketing aspects of MED3000 including launch will be handled by them.

       

    • When will MED3000 be on the market in the US?

      In March 2020, Futura announced that it had received  official minutes from the US Food and Drug Administration (FDA) for MED3000, the Company’s breakthrough fast acting clinically proven treatment for erectile dysfunction (“ED”), following its 4th Pre-Submission Meeting on 1st February 2021.

      The minutes signify agreement between the FDA and Futura on the detailed clinical study design (protocol) for the small confirmatory clinical study, FM71, to be conducted prior to formal regulatory submission as a De Novo Medical Device. Detailed planning for the commencement of FM71 has now begun with first patient dosing expected H2 2021.  The company currently expects submission for marketing authorisation within the USA to be made during H2 2022 with approval as soon as practicable thereafter.

    • When will MED3000 be on the market in the rest of the world?

      European approval for MED3000 will be final upon issuance of a Medical Device Regulation certificate by the EU Notified Body which is expected before the end of May.

      Once EU certification and the resultant CE mark is granted, this paves the way for rapid approval in many countries around the world in regions including the Middle East, Africa, the Far East and Latin America, who allow "fast-track" review based on their recognition of the EU CE mark. Depending on the country these approvals are likely to take between 6 and 12 months from the time of submission.

    • When is Futura Medical looking to start the new clinical trial, FM71?

      As mentioned in the March 2021 RNS, the Company confirmed that it had received official minutes from the US FDA, following its 4th Pre-Submission Meeting on 1st February 2021.

      The minutes signify agreement between the FDA and Futura on the detailed clinical study design (protocol) for the small confirmatory clinical study, FM71, to be conducted prior to formal regulatory submission as a De Novo Medical Device. Detailed planning for the commencement of FM71 has now begun with first patient dosing expected H2 2021.

    • What is the FM71 clinical study?

      FM71 is designed to provide supplementary efficacy data to the previously reported FM57 study with a "least burdensome" approach and modest cost. Whilst the overall design is similar to that of the previous large phase 3 FM57 study that recruited approximately 1000 patients, no placebo (sham) cohort is required, hence the study is relatively small in size with approximately 100 patients.

      FM71 will be a 6 month (24 weeks) duration study versus FM57 which was conducted over 3 months (12 weeks) to reassure the FDA that the efficacy does not diminish over a longer period of time. It is Futura's belief that this is unlikely as in the FM57 study efficacy improved from the first to third month of patient use. Two co-primary endpoints will measure change from baseline and whether this change is clinically important, both criteria being achieved in FM57 over the 12 week duration of the study Secondary endpoints include an agreed measure of speed of onset, a key differentiating claim, where FM57 showed that 60% of subjects noticed an erection within 10 minutes.

      The Company has agreed with the FDA to include tadalafil (Cialis®) at the lowest approved dose for on-demand use (5mg) for comparative purposes only on safety, speed of onset and efficacy; non-inferiority is not required to be shown.

      FM71 is designed as a phase 3, multicentre, comparative, randomised, open-label, home use, parallel group study.  The recruited patients will include those suffering from mild, moderate or severe ED, using either MED3000 or tadalafil 5mg (50 subjects per group) and will include 20 African American patients (from a US medical centre) and 80 patients recruited from Eastern Europe where sites include some of the same centres used in the FM57 study. 

    • Can I participate in the MED3000 clinical trial/Can I try this product?/Can I become a test patient? How can I apply for the clinical trial?

      Per the regulatory update on 22nd March 2021, the Company is pleased to confirm that it has received official minutes from the FDA, following its 4th Pre-Submission Meeting held 1st February 2021.

      The minutes signify agreement between the FDA and Futura on the detailed clinical study design (protocol) for the small confirmatory clinical study, FM71, to be conducted prior to formal regulatory submission as a De Novo Medical Device.

      Detailed planning for the commencement of FM71 has now begun with first patient dosing expected H2 2021.

      Patients interested in participating will be able to find details in due course on clinicaltrials.gov.

    • Will MED3000 work if I have had a prostatectomy?

      At this time we have not tested the product in patients who have undergone radical prostatectomy although the product has been shown to be effective in mild, moderate and severe ED of mixed causes.

    • Can I use MED3000 if I have a medical condition?

      If you have a medical condition you may need to speak to a doctor to discuss your condition to see if the product is suitable for you to use. 

      MED3000 will come with a leaflet part of which will cover warning and precautions and recommend users have a check-up with your doctor as soon as possible within the first 6 months of using MED3000 to ensure that any erection problems are not caused by another serious health condition.

    • When MED3000 launches what do you expect will be the shelf life?

      We anticipate a shelf life of 3 years.

    • What is the difference between Eroxon®, MED2002, MED2005 and MED3000?

      What is the difference between Eroxon®, MED2002 and MED2005 and MED3000?

      Eroxon® is the registered and suggested brand name for Futura’s topical gel for ED, though potential distributors may choose to use other brand names.

      MED3000 is now the codename for the final formulation of DermaSys® developed specifically for the treatment of ED. MED2005 or MED2002 are the codenames used by Futura for earlier proprietary formulations.

    • What were the results of the European Phase 3 study, FM57?

      Results of the FM57 study can be found here

    • When do you expect Thornton & Ross to obtain regulatory approval within the UK?

      In February 2019, the UK Medicines and Healthcare products Regulatory Agency (MHRA) responded to Thornton & Ross’s marketing authorisation application filed in July 2018, raising a number of questions requiring additional laboratory work specifically around the permeation characteristics of TPR100 to be conducted. The additional lab work has been completed indicating that absorption of TPR100 is significantly superior to the market leader. These results were discussed with MHRA in a Scientific Advice meeting and it was determined that as there was non-equivalency a clinical study was required. MHRA suggested that the clinical study could be used to support superiority claims for the formulation. FUM are determining how this study could be funded and used to support the product in markets around the world including the US where Voltaren (GSK) have recently achieved OTC designation.

       

    • What formulation of DermaSys® is used for the TPR100 product? How does this differ from MED3000?

      Our transdermal technology DermaSys® is tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action offering improvements over existing products creating novel indications with compelling commercial potential. This means that our products are highly differentiated in their markets whilst avoiding the risks normally associated with the development of new molecules.

      The rapid skin permeation rate offered by our transdermal delivery system, DermaSys®, is ideally suited for targeted topical pain relief. Rapid, targeted and effective skin permeation offers potential benefits in pain management including: improved onset of action, duration and degree of pain relief.

      TPR100 does not require a combination of volatile solvent components to stimulate nerve sensors.  It is designed to provide a sustained mode of action suitable for the treatment of pain and is formulated with this objective in mind.

    • What is the IP position of this specific formulation?

      TPR100's current patent protection runs until February 2028 in the USA and Europe.

    • Who are CBDerma Technology Ltd?

      CBDerma Techology is a company that has been established with backers that have experience in plant derived products.  Futura announced a joint venture collaboration with CBDerma Technology Limited in September 2019 to explore the application of Futura’s advanced proprietary transdermal technology, DermaSys® for the delivery of cannabidiol.

       

    • What are the potential market sizes for cannabidiol either as a cosmetic or a pharmaceutical?

      The cosmetic market is already significant with the UK, we understand, over £300 million. As a topically applied Pharmaceutical the potential is huge but under-explored so far, with currently very little credible scientific research conducted on topical formulations.

    • Why is DermaSys® an ideal product formulation for cannabidiol?

      DermaSys® provides rapid and targeted local delivery of active pharmaceutical ingredients (API) at therapeutic levels and Generally Recognized As Safe (GRAS) pharmaceutical excipients onto and through the skin to the required site of action with a high level of safety. It is a versatile and bespoke technology that can be tailored to suit the specific active compound being used and the therapeutic indication. Each product is formulated to maximise its benefits for patients and consumers and can be developed for the prescription and consumer healthcare markets as appropriate.

    • What formulation of DermaSys® is used for the CBD100 product? How does this differ from MED3000?

      Our transdermal technology DermaSys® is tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action offering improvements over existing products creating novel indications with compelling commercial potential. This means that our products are highly differentiated in their markets whilst avoiding the risks normally associated with the development of new molecules.

      CBD100 comprises a unique combination of penetration enhancers (volatile and non-volatile solvents) and a diffusion enhancer.  It is designed to provide highly efficient penetration of cannabidiol into and through the skin with a stability expected to ensure potency is retained during shelf-life.

    • What is the IP position of this specific formulation?

      A patent application was filed in the UK in August 2020.

    • When will you hear back about the CBD100 patent application?

      We would expect to receive an initial search report on the ‘patentability’ of such application within six months.  This will provide details of other patents or application already in existence which may affect the novelty and inventiveness of any new application.  This may result in some amendment to the patent application ahead of a PCT application next July.

    • What will be the next steps with CBD100?

      We are aiming for CBD100 to be highly differentiated from existing, largely un-regulated, low-tech products in the fast growing cannabidiol market on the basis of quality, stability and efficient delivery to the skin for a number of applications and indications expected to range from cosmeceutical through to pharmaceutical dermal and pain relief treatments. We have now started to explore commercialisation options for CBD100 with CBDerma as stability work continues in parallel.  These options will also be influenced by the regulatory landscape around Cannabis which continues to evolve in the EU and USA.

    • Can I request a sample of CBD1000?

      Unfortunately, under the current regulations, Futura Medical are not able to provide samples.

    Futura Medical logo

    ©2021 Futura Medical

    • Sitemap
    • Contact us
    • Accessibility
    • Terms of use
    • Privacy & cookies policies

    Designed and developed by
    jonesandpalmer.co.uk